임상 레이더 AI | ||
|---|---|---|
임상시험 NCT07479355 (ECRAN-PLASMA)은(는) 폐렴에 대해 진행중, 모집종료 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요. | ||
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
검색으로 돌아가기
파리 공립병원 연합Study of the Characteristics of Acute Mycoplasma Resuscitation: ECRAN-PLASMA Study 100
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT07479355 (ECRAN-PLASMA)은(는) 폐렴에 대해 알아보는 관찰연구입니다. 현재 상태는 진행중, 모집종료이며, 연구는 2024년 9월 15일에 시작되어 100명의 참여자를 모집하고 있습니다. 파리 공립병원 연합이(가) 진행하며, 2026년 6월 15일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 3월 18일에 갱신되었습니다.
간단한 개요
The ECRAN-PLASMA study aims to analyze the characteristics of patients with Mycoplasma pneumoniae or Chlamydia pneumoniae pneumonia hospitalized in intensive care units (ICU), continuous monitoring units (USC), or intensive pulmonary care units (USIP). It evaluates their management, prognosis, and macrolide resistance rates.
상세한 설명
The ECRAN-PLASMA study focuses on Mycoplasma pneumoniae and Chlamydia pneumoniae infections in intensive care units (ICU), continuous monitoring units (USC), and intensive pulmonary care units (USIP). It aims to better understand the epidemiology, management, and prognosis of these infections, particularly in light of the resurgence of cases following the COVID-19 pandemic and the increasing resistance to macrolides....더 보기
공식 제목
Study of the Characteristics of Acute Mycoplasma Resuscitation: ECRAN-PLASMA Study
질환명
폐렴기타 연구 식별자
- ECRAN-PLASMA
- APHP240404
NCT 번호
실제 연구 시작일
2024-09-15
최신 업데이트 게시
2026-03-18
예상 연구 완료일
2026-06-15
계획된 등록 인원
100
연구종류
관찰연구
상태
진행중, 모집종료
키워드
Intensive Care Unit (ICU)
Intensive Respiratory Care Unit (USIP)
Intermediate Care Unit (USC)
Chlamydia pneumoniae
Mycoplasma pneumoniae
Infection
Intensive Respiratory Care Unit (USIP)
Intermediate Care Unit (USC)
Chlamydia pneumoniae
Mycoplasma pneumoniae
Infection
시험군 / 개입
| 참가자 그룹/시험군 | 개입/치료 |
|---|---|
해당 없음 | Infectious disease epidemiology evaluation of patient management, prognosis, and macrolide resistance rates in severe Mycoplasma pneumoniae and Chlamydia pneumoniae infections. |
주요결과변수
이차결과변수
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Incidence of Severe Mycoplasma pneumoniae and Chlamydia pneumoniae Infections | Number of patients hospitalized in ICU, USC, or USIP with a confirmed diagnosis of Mycoplasma pneumoniae or Chlamydia pneumoniae. | From hospital admission to hospital discharge (up to 60 days) |
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
In-hospital Mortality Rate | Proportion of patients who died during the index hospitalization among patients with confirmed infection, assessed from medical records. | From hospital admission to hospital discharge (up to 60 days) |
Length of Stay in ICU and Hospital | Number of days spent in the ICU and total hospitalization duration. | From hospital admission to hospital discharge (up to 60 days) |
Macrolide Resistance Rate | Percentage of patients infected with a macrolide-resistant strain. | At time of microbiological diagnosis (baseline) |
Need for invasive mechanical ventilation | Proportion of patients requiring invasive mechanical ventilation during hospitalization, assessed from medical records. | From hospital admission to hospital discharge (up to 60 days) |
Use of respiratory and supportive therapies | Proportion of patients receiving each therapeutic modality (oxygen therapy, non-invasive ventilation, invasive mechanical ventilation, ECMO) during hospitalization, assessed from medical records. | From hospital admission to hospital discharge (up to 60 days) |
Time from Symptom Onset to ICU Admission | Time elapsed between the onset of symptoms and hospitalization in USC, USIP, or ICU. | At patient admission. |
In-hospital mortality compared with other bacterial pneumonias | Difference in in-hospital mortality rates between patients with Mycoplasma or Chlamydia pneumoniae infection and patients with other bacterial pneumonias, assessed from medical records. | From hospital admission to hospital discharge (up to 60 days) |
Vital status at hospital discharge | Proportion of patients alive at hospital discharge, assessed from medical records. | During hospitalization (up to 60 days) |
Respiratory support at hospital discharge | Proportion of patients requiring respiratory support (oxygen therapy or mechanical ventilation) at hospital discharge, assessed from medical records. | During hospitalization (up to 60 days) |
Occurrence of acute respiratory distress syndrome (ARDS) | Proportion of patients who developed acute respiratory distress syndrome during hospitalization, assessed from medical records. | From hospital admission to hospital discharge (up to 60 days) |
참여 도우미
적격성 기준
연령대
성인, 노인
최소 연령
18 Years
참여 가능한 성별
전체
- Screening of all patients hospitalized in Intermediate Care Units (USC), Intensive Respiratory Care Units (USIP), and Intensive Care Units (ICU)
- Inclusion of patients who test positive for Mycoplasma pneumoniae or Chlamydia pneumoniae
- Patients under 18 years old
파리 공립병원 연합967개의 진행 중인 임상시험 탐색 가능연락처 정보가 없습니다.
1 1개국에 임상시험 장소
Medecine intensive-reanimation, Le Kremlin-Bicêtre, France